Q&A: Rentschler’s CEO On The CDMO’s Pivot Away From Cell And Gene Therapy And More

 
• By David Wild
  
Benedikt von Braunmühl
Benedikt von Braunmühl, CEO, Rentschler Biopharma (Rentschler)

More from Manufacturing Focus

More from Leadership